Clinical update

New drug therapy for myeloma

A collaboration between Cancer Drugs Fund and National Institute for Health and Care Excellence has produced a new drug therapy available to some patients with myeloma

A collaboration between Cancer Drugs Fund and National Institute for Health and Care Excellence has produced a new drug therapy available to some patients with myeloma

Essential facts

Myeloma, a cancer that develops from plasma cells in the bone marrow, is diagnosed in approximately 5,500 people in the UK each year. In 2014 it was the reason given for nearly 3,000 deaths. Cancer Research UK statistics show that about a third of patients with myeloma survive for ten years or more.

What’s new?

An innovative immunotherapy drug treatment for myeloma, daratumumab, was recently approved for use in the Cancer Drugs Fund in England and Wales by the National Institute for Health and Care Excellence (NICE). But it will only be available to patients who have had three previous lines of treatment and whose myeloma has since

...

Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?

Jobs